U.S. Hemato Oncology Testing Market Size & Outlook
U.S. hemato oncology testing market, 2018-2028 (US$M)
Related Markets
U.S. hemato oncology testing market highlights
- The U.S. hemato oncology testing market generated a revenue of USD 695.6 million in 2020 and is expected to reach USD 2,030.6 million by 2028.
- The U.S. market is expected to grow at a CAGR of 14.3% from 2021 to 2028.
- In terms of segment, lymphoma was the largest revenue generating cancer type in 2020.
- Lymphoma is the most lucrative cancer type segment registering the fastest growth during the forecast period.
Hemato oncology testing market data book summary
| Market revenue in 2020 | USD 695.6 million |
| Market revenue in 2028 | USD 2,030.6 million |
| Growth rate | 14.3% (CAGR from 2020 to 2028) |
| Largest segment | Lymphoma |
| Fastest growing segment | Lymphoma |
| Historical data | 2018 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Leukemia, Lymphoma, MPNs, Other Cancers |
| Key market players worldwide | Roche Holding AG, Abbott Laboratories, Qiagen NV, Danaher Corp, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Illumina Inc, Bio-Techne Corp |
Other key industry trends
- In terms of revenue, U.S. accounted for 29.9% of the global hemato oncology testing market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In North America, U.S. hemato oncology testing market is projected to lead the regional market in terms of revenue in 2028.
- Canada is the fastest growing regional market in North America and is projected to reach USD 485.7 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hemato Oncology Testing Market Scope
Hemato Oncology Testing Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. hemato oncology testing market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hemato oncology testing market will help companies and investors design strategic landscapes.
Lymphoma was the largest segment with a revenue share of 46.89% in 2020. Horizon Databook has segmented the U.S. hemato oncology testing market based on leukemia, lymphoma, mpns, other cancers covering the revenue growth of each sub-segment from 2018 to 2028.
The U.S. accounted for the largest share in North America hemato oncology testing market and is anticipated to maintain its dominance during the forecast period owing to high healthcare expenditure, increase in adoption of novel solutions, rise in number of approvals, and commercialization of various technologically advanced hemato oncology testing solutions.
For instance, in October 2019, Cepheid received U.S. FDA clearance for its Xpert BCR-ABL Ultra. Xpert BCR-ABL Ultra in vitro diagnostic test intended to monitor disease burden in patients with Chronic Myeloid Leukemia (CML).
In addition, in 2018, the U.S. FDA allowed marketing of ClonoSEQ assay, an NGS-based test for minimal residual disease in patients with multiple myeloma or acute lymphoblastic leukemia. Moreover, in October 2021, Sysmex Inostics developed a new Clinical Laboratory Improvement Amendments—a validated liquid biopsy test for the detection of MRD in acute myeloid leukemia.
Reasons to subscribe to U.S. hemato oncology testing market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. hemato oncology testing market databook
-
Our clientele includes a mix of hemato oncology testing market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. hemato oncology testing market , including forecasts for subscribers. This country databook contains high-level insights into U.S. hemato oncology testing market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. hemato oncology testing market size, by cancer type, 2018-2028 (US$M)
U.S. Hemato Oncology Testing Market Outlook Share, 2020 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
